CORT

Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).Conference Call InformationParticipants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN.

President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.

The transaction involved 40,000 shares with an estimated value of $3.5 million on the July 15, 2026 transaction date. The activity was executed through the conversion of 40,000 options at $19.26 and $23.06 per share, which were immediately liquidated.

The transaction involved the sale of 10,000 shares at $88.30 per share, resulting in a total value of $883,000 on July 15, 2026. The sale reduced the insider's total indirect equity holdings by 0.67%.

The transaction realized $1.9 million in gross proceeds on July 7, 2026, at a weighted average price of $93.13 per share. The disposition was a cashless exercise of 20,000 options at a strike price of $21.65, followed by an immediate open-market sale.

Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant's FDA approval in ovarian cancer and likely approval in Cushing's syndrome could drive CORT revenues above $3 billion annually by decade's end. 2026 revenue guidance of $950M–$1.05B reflects >30% YoY growth, with minimal impact expected from generic competition due to pipeline innovation.

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.

CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders.